FTC Has Put PBMs, PBM Rebates in its Hot Seat
Written by Black Hot Fire Network on June 18, 2022
A week after announcing a study of the PBM industry, the Federal Trade Commission announced yesterday that it was stepping up possible enforcement actions targeting the industry's rebate practices. Rebates to exclude lower costs from formularies may constitute commercial bribery under the Robinson-Patman Act, the commission said.
On the heels of an announcement last week that it was going to conduct a thorough study of the pharmaceutical benefits management (PBM) industry, the Federal Trade Commission announced yesterday that it was ramping up possible enforcement action against PBMs, zeroing on rebate practice that, in . . .
